ISIN | LU0115986761 |
---|---|
Valor Number | 1113164 |
Bloomberg Global ID | |
Fund Name | RH&P Global Life Sciences Fund A CAP USD |
Fund Provider |
RH&PARTNER Investment Funds
Basel, Switzerland Phone: +41 61 378 83 63 E-Mail: info@rh-finanz.ch Web: https://www.rh-finanz.ch |
Fund Provider | RH&PARTNER Investment Funds |
Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
Distributor(s) |
Banque Pictet & Cie SA
Credit Suisse Zürich UBS n/a Vontobel n/a |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | N/A |
Peculiarities |
Current Price * | 171.16 USD | 27.03.2025 |
---|---|---|
Previous Price * | 170.53 USD | 26.03.2025 |
52 Week High * | 188.29 USD | 08.11.2024 |
52 Week Low * | 155.34 USD | 19.04.2024 |
NAV * | 171.16 USD | 27.03.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 60,472,781 | |
Unit/Share Assets *** | 57,363,999 | |
Trading Information SIX |
YTD Performance | -0.08% |
31.12.2024 - 27.03.2025
31.12.2024 27.03.2025 |
---|---|---|
YTD Performance (in CHF) | -2.97% |
31.12.2024 - 27.03.2025
31.12.2024 27.03.2025 |
1 month | -4.22% |
27.02.2025 - 27.03.2025
27.02.2025 27.03.2025 |
3 months | -1.39% |
27.12.2024 - 27.03.2025
27.12.2024 27.03.2025 |
6 months | -5.77% |
27.09.2024 - 27.03.2025
27.09.2024 27.03.2025 |
1 year | +1.46% |
27.03.2024 - 27.03.2025
27.03.2024 27.03.2025 |
2 years | +3.75% |
27.03.2023 - 27.03.2025
27.03.2023 27.03.2025 |
3 years | +1.53% |
28.03.2022 - 27.03.2025
28.03.2022 27.03.2025 |
5 years | +9.00% |
27.03.2020 - 27.03.2025
27.03.2020 27.03.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Charles River Laboratories International Inc | 4.53% | |
---|---|---|
Bio-Techne Corp | 4.46% | |
Nektar Therapeutics | 4.36% | |
Illumina Inc | 3.93% | |
Exelixis Inc | 3.87% | |
Alkermes PLC | 3.72% | |
IQVIA Holdings Inc | 3.65% | |
Biogen Inc | 3.59% | |
Amgen Inc | 3.57% | |
Incyte Corp | 3.53% | |
Last data update | 30.04.2021 |
TER *** | 2.40% |
---|---|
TER date *** | 30.06.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.40% |
Ongoing Charges *** | 2.35% |
SRRI ***
|
|
SRRI date *** | 28.02.2025 |